

HEARUSA INC  
Form 424B3  
September 01, 2005

PROSPECTUS SUPPLEMENT NO. 1  
TO PROSPECTUS DATED JUNE 10, 2004**HEARUSA, INC.**  
9,661,308 SHARES OF  
COMMON STOCK

This Prospectus Supplement supplements the Prospectus dated June 10, 2004 (the "Prospectus") and relates to the resale by selling stockholders of the securities described in the Prospectus. This Prospectus Supplement should be read in conjunction with the Prospectus, which is to be delivered by selling stockholders to prospective purchasers along with this Prospectus Supplement. Capitalized terms not defined herein have the meaning ascribed to them in the Prospectus.

The information in the "Selling Stockholders" section beginning on page 7 of the Prospectus is hereby amended to reflect: (a) the transfer of a warrant by Steven J. Hansbrough to Graham Partners, L.P. and to Stephen Trager Watson; (b) the transfer of Notes and Note Warrants, resulting from the expiration of stockholder Millicom 2000 Grat, to a successor trustee, Selz Family 1997 Trust; (c) the surrender by Barry Bloomfield of a warrant exercisable for 50,000 shares of common stock; (d) the transfer by Adelpia Holdings, LLC to two of its principals; and (e) additional and updated information concerning beneficial ownership of the Company's common stock. The table below sets forth supplemental and updated information about the selling stockholders and the number of shares of common stock beneficially owned, and supersedes the table appearing in the Prospectus. For purposes of calculating the percentage of common stock beneficially owned after the offering, as of July 31, 2005, 31,935,402 shares of our common stock (including exchangeable shares) were outstanding.

Name of Selling Shareholder	Shares Beneficially Owned Prior to Offering	Shares Being Offered	Shares Beneficially Owned After Offering	% of Common Stock Beneficially Owned After Offering (if greater than 1%)
Alexandra Global Master Fund	857,129	857,129	0	
Thomas W. Archibald <sup>(2)</sup>	240,100 <sup>(1)</sup>	50,000 <sup>(1)</sup>	190,100	
Atlas Capital Master Fund, L.P.	1,285,693 <sup>(3)</sup>	1,285,693	0	
Atlas Capital (Q.P.) L.P.	428,564 <sup>(1)</sup>	428,564 <sup>(1)</sup>	0	
Barry A. Bloomfield	100,000 <sup>(6)</sup>	50,000 <sup>(6)</sup>	50,000	
Paul A. Brown, M.D. <sup>(4)</sup>	2,415,000 <sup>(5)(6)</sup>	695,000 <sup>(6)</sup>	1,720,000	5.39%

Name of Selling Shareholder	Shares Beneficially Owned Prior to Offering	Shares Being Offered	Shares Beneficially Owned After Offering	% of Common Stock Beneficially Owned After Offering (if greater than 1%)
Peter N. Christos	25,000	25,000	0	
Flyline Holdings, Ltd.	428,564 <sup>(1)</sup>	428,564 <sup>(1)</sup>	0	
Gestion Fremican Inc. <sup>(7)</sup>	893,928 <sup>(6)</sup>	160,000 <sup>(6)</sup>	733,928	2.30%
Joseph L. Gitterman III <sup>(2)</sup>	334,764 <sup>(9)</sup>	150,000	184,764	
Graham Partners, L.P.	261,000	50,000	210,000	
Jesup & Lamont Securities Corporation	40,000 <sup>(8)</sup>	40,000 <sup>(8)</sup>	0	
J.P. Carey Securities, Inc.	57,143 <sup>(8)</sup>	57,143 <sup>(8)</sup>	0	
Kennebec Resources, Inc.	444,264 <sup>(10)</sup>	444,264 <sup>(10)</sup>	0	
Arnold P. Kling	25,000	25,000	0	
The Kriegsmann Group	200,000	200,000	0	
David J. McLachlan <sup>(2)</sup>	198,045 <sup>(3)</sup>	50,000	148,045	
Micro Capital Fund Ltd.	128,569 <sup>(1)</sup>	128,569 <sup>(1)</sup>	0	
Micro Capital Fund LP	299,995 <sup>(1)</sup>	299,995 <sup>(1)</sup>	0	
175778 Canada, Inc. <sup>(11)</sup>	236,046 <sup>(6)</sup>	160,000 <sup>(6)</sup>	76,046	
Richard Press	500,000 <sup>(6)</sup>	140,000 <sup>(5)</sup>	360,000	1.13%
Brandon Ross	16,000 <sup>(8)</sup>	16,000 <sup>(8)</sup>	0	
Louis Schwartz	25,400	10,000	15,400	
Chris Sebastian	15,000	10,000	5,000	
Selz Family 1997 Trust	857,129 <sup>(1)</sup>	857,129 <sup>(1)</sup>	0	
Andrew Siegel	150,000	75,000	75,000	
Jack Silver	1,000,000 <sup>(12)</sup>	1,000,000 <sup>(12)</sup>	0	
Paul Silverstein, M.D.	200,000	100,000	100,000	
Sherleigh Associates Inc. Profit Sharing Plan	1,714,258 <sup>(1)</sup>	1,714,258 <sup>(1)</sup>	0	
George Tabuas	4,000 <sup>(9)</sup>	4,000 <sup>(9)</sup>	0	
Stephen Trager Watson	50,000	50,000	0	
Herbert Weiss	23,000	15,000	8,000	
Robert Willis, M.D.	515,000 <sup>(13)</sup>	85,000 <sup>(13)</sup>	430,000	1.35%
<b>Total</b>	<b>13,968,591</b>	<b>9,661,308</b>	<b>4,307,283</b>	

(1) Assumes conversion of HearUSA 2003 convertible subordinated notes due November 30, 2008 (the Notes) at a conversion price of \$1.75, with all accrued interest paid in cash, and exercise of warrants issued in connection therewith (the Notes Warrants). Includes shares underlying Notes and Notes Warrants exercisable only after December 2005. Includes shares underlying Notes Warrants to purchase a number of shares of common stock that, when taken together with the number of shares of common stock issuable upon conversion of the Notes currently outstanding and exercise of the other Notes Warrants currently outstanding, could exceed the number of shares of common stock that may be issued without shareholder approval under the rules and regulations of the American Stock Exchange.

- (2) Director of HearUSA.
- (3) Includes 34,000 shares of common stock issuable upon the exercise of non-qualified options, all of which are currently exercisable.
- (4) Chairman of the Board of HearUSA.
- (5) Includes 100,000 shares of common stock subject to options which are currently exercisable (or exercisable within 60 days).
- (6) Includes shares underlying warrants exercisable only from and after October 2005.

- (7) Michel Labadie, a director of HearUSA, is a director and shareholder of this company. The shares reflected in the table as beneficially owned by Mr. Labadie's company exclude 42,685 shares subject to currently exercisable options owned by Mr. Labadie in his individual capacity, and 1,485,540 shares and 106,110 shares subject to options which are currently exercisable which are owned by Les Partenaires de Montréal, s.e.c. ( Montreal Partners ). Mr. Labadie is a director of Les Partenaires de Montréal Inc., the general partner of Montreal Partners.
- (8) Includes shares underlying warrants exercisable only from and after December 2005.
- (9) Includes 29,500 shares of common stock issuable upon the exercise of non-qualified options, all of which are currently exercisable.
- (10) Includes 428,564 shares underlying Notes and Notes Warrants (see footnote 1).
- (11) Pierre Bourgie, a former director of HearUSA, is a director and shareholder of this company. The shares reflected in the table as beneficially owned by Mr. Bourgie's company exclude 25,000 shares subject to currently exercisable options owned by Mr. Bourgie in his individual capacity, and 1,485,540 shares and 106,110 shares subject to options which are currently exercisable which are owned by Montreal Partners. Mr. Bourgie is a director of Les Partenaires de Montréal Inc., the general partner of Montreal Partners.
- (12) Includes 300,000 shares underlying warrants which are currently exercisable, 200,000 shares underlying warrants exercisable only from and after October 2005 and 500,000 shares underlying warrants exercisable only after June 2005.
- (13) Includes shares held by trusts of which Mr. Willis serves as trustee.

Information about selling stockholders may change over time. Changed information of which we become aware will be set forth in prospectus supplements to the extent required by the Securities Act of 1933, as amended, and the rules thereunder. We also will set forth in prospectus supplements any other additional information relating to selling stockholders to the extent so required.

NEITHER THE SECURITIES AND EXCHANGE COMMISSION NOR ANY STATE SECURITIES COMMISSION HAS APPROVED OR DISAPPROVED OF THESE SECURITIES OR PASSED UPON THE ADEQUACY OR ACCURACY OF THIS PROSPECTUS SUPPLEMENT. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE.

This Prospectus Supplement is dated August 31, 2005.

PROSPECTUS

# HearUSA, Inc.

## Common Stock

The selling shareholders may offer to sell from time to time up to 9,711,308 shares of the common stock of HearUSA, Inc. Some of these shares are underlying warrants and convertible notes. Many of these shares can be sold by the selling shareholders only after certain agreed upon holding periods have expired. HearUSA will not receive any of the proceeds from sales of these shares of common stock by the selling shareholders, although we might receive cash proceeds from the exercise of warrants by the selling shareholders prior to the sale of the shares underlying these warrants.

The selling shareholders may sell the shares of common stock offered by this prospectus at prices determined by the prevailing market prices for the common stock or in negotiated transactions. The selling shareholders may also sell the shares to or with the assistance of broker-dealers.

HearUSA common stock is traded on the American Stock Exchange under the symbol EAR. On June 3, 2004, the last reported sale price of the common stock on the American Stock Exchange was \$1.86 per share.

Before buying any shares, you should read the discussion of risks under Risk Factors beginning on page 2.

**Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.**

The date of this prospectus is June 10, 2004

---

TABLE OF CONTENTS

	<u>Page</u>
<u>THE COMPANY</u>	1
<u>RISK FACTORS</u>	2
<u>FORWARD-LOOKING STATEMENTS</u>	7
<u>USE OF PROCEEDS</u>	7
<u>SELLING SHAREHOLDERS</u>	7
<u>PLAN OF DISTRIBUTION</u>	10
<u>COMMON STOCK</u>	11
<u>AVAILABLE INFORMATION</u>	11
<u>INFORMATION INCORPORATED BY REFERENCE</u>	11
<u>LEGAL MATTERS</u>	12
<u>EXPERTS</u>	12

---

**THE COMPANY**

HearUSA, Inc. has a network of 156 company-owned hearing care centers in 11 states and the Province of Ontario, Canada. We also sponsor approximately 1,400 credentialed audiology providers as part of a nationwide network of providers that participate in selected hearing benefit programs contracted by the company with employer groups, health insurers and benefit sponsors in 49 states. The centers and the network providers provide audiological products and services for the hearing impaired.

We seek to increase our market share and market penetration in our center and network markets through creative marketing and an organized delivery system that targets both the medical and consumer communities. Our strategy for increasing market penetration includes advertising to the non-insured self-pay market, positioning our company as the leading provider of hearing care to healthcare providers and increasing awareness of physicians about hearing care services and products in our geographic markets. We believe we are well positioned to successfully address the concerns of access, quality and cost for the patients of managed care and other health insurance companies; the diagnostic needs of referring physicians; and ultimately, the hearing health needs of the public in general.

HearUSA was incorporated in Delaware on April 11, 1986 under the name HEARx Ltd., and formed HEARx West LLC, a fifty-percent owned joint venture with Kaiser Permanente, in 1998. In July 2002, we acquired Helix Hearing Care of America Corp. and changed our name from HEARx Ltd. to HearUSA, Inc. Our principal executive offices are located at 1250 Northpoint Parkway, West Palm Beach, Florida 33407, and our telephone number is (561) 478-8770.

## RISK FACTORS

This offering involves a high degree of risk. You should carefully consider the following risks and all other information contained and incorporated by reference in this prospectus before purchasing the common stock offered by this prospectus. The risks and uncertainties described below are not the only ones facing us. Additional risks and uncertainties that we are unaware of may become important factors that affect us. If any of the following risks occur, our business, financial condition and results of operations could be materially and adversely affected. In that event, the trading price of our shares could decline, and you may lose part or all of your investment.

***HearUSA has a history of operating losses and may never be profitable.***

HearUSA has incurred net losses in each year since its organization, and its accumulated deficit at March 27, 2004 was \$100,117,660. We expect quarterly and annual operating results to fluctuate, depending primarily on the following factors:

Timing of product sales;

Level of consumer demand for our products;

Timing and success of new centers; and

Timing and amounts of payments by health insurance and managed care organizations.

There can be no assurance that HearUSA will achieve profitability in the near or long term or ever.

***We may not effectively compete in the hearing care industry.***

The hearing care industry is highly fragmented and barriers to entry are low. Approximately 11,000 practitioners provide testing and dispense products and services that compete with those provided and sold by HearUSA. We also compete with small retailers, as well as large networks of franchisees and distributors established by larger companies, such as those manufacturing and selling Miracle Ear and Beltone products. Some of the larger companies have far greater resources than HearUSA and could expand and/or change their operations to capture the market targeted by HearUSA. Large discount retailers, such as Costco Wholesale Corporation, also sell hearing aids and present a competitive threat in our markets. In addition, it is possible that the hearing care market could be effectively consolidated by the establishment of cooperatives, alliances or associations that could compete more successfully for the market targeted by us.

***We are dependent on manufacturers who may not perform.***

HearUSA is not a hearing aid manufacturer. We rely on major manufacturers to supply our hearing aids and to supply hearing enhancement devices. A significant disruption in supply from any or all of these manufacturers could materially adversely affect our business. Our strategic and financial relationship with Siemens Hearing Instruments, Inc. requires us to purchase from Siemens a certain portion of our requirements of hearing aids at specified prices for a period of ten years, with separate requirements for each five-year period. Although Siemens is the world's largest manufacturer of hearing devices, there can be no assurance that Siemens' technology and product line will remain desirable in the marketplace. Furthermore, if Siemens' manufacturing capacity cannot keep pace with the demand of HearUSA and other customers, our business may be adversely affected.

***We rely on qualified audiologists, without whom our business may be adversely affected.***

HearUSA currently employs 186 licensed hearing professionals, of whom 139 are audiologists and 47 are licensed hearing aid specialists. If we are not able to attract and retain qualified audiologists, we will be less able to compete with networks of hearing aid retailers or with the independent audiologists who also sell hearing aids, and our business may be adversely affected.

***We may not be able to maintain existing agreements or enter into new agreements with health insurance and managed care organizations, which may result in reduced revenues.***

HearUSA enters into provider agreements with health insurance companies and managed care organizations for the furnishing of hearing care in exchange for fees. The terms of most of these agreements are to be renegotiated annually, and these agreements may be terminated by either party on 90 days or less notice at any time. There is no certainty that we will be able to maintain these agreements on favorable terms or at all. If we cannot maintain these contractual arrangements or enter into new arrangements, there will be a material adverse effect on our revenues and results of operations. In addition, the early termination or failure to renew the agreements that provide for payment to HearUSA on a per-patient-per-month basis would cause us to lower our estimates of revenues to be received over the life of the agreements. This could have a material adverse effect on our results of operations.

***We depend on our joint venture for our California operations and may not be able to attract sufficient patients to our California centers without it.***

HEARx West LLC, our joint venture with Kaiser Permanente, operates 20 full-service centers in California as well as two satellite locations in Kaiser facilities. Since their inception, HEARx West centers have derived approximately two-thirds of their revenues from sales to Kaiser Permanente members, including revenues through an agreement between the joint venture and Kaiser Permanente's California division servicing its hearing benefited membership. If Kaiser Permanente does not perform its obligations under the agreement, or if the agreement is not renewed upon expiration, the loss of Kaiser patients in the HEARx West centers would adversely affect our business. In addition, HEARx West centers would be adversely affected by the loss of the ability to market to Kaiser members and promote the business within Kaiser's medical centers, including the referral of potential customers by Kaiser.

***We rely on the efforts and success of managed care companies that may not be achieved or sustained.***

Many managed care organizations, including some of those with whom we have contracts, have experienced and are continuing to experience significant difficulties arising from the widespread growth and reach of available plans and benefits. In fact, primarily as a result of these problems of the managed care organizations, we have focused marketing resources on the self-pay market and have, since 1999, closed or relocated 15 of our centers primarily in the Northeast and Florida. There can be no assurance that we can maintain all of our centers. We will close centers where warranted, and such closures could have a material adverse effect on us.

***We may not be able to maintain JCAHO accreditation, and our revenues may suffer.***

During 1998, HearUSA was awarded a three-year accreditation from the Joint Committee on Accreditation of Healthcare Organizations (JCAHO). We applied and were granted renewal of this accreditation for the Hearx centers for an additional three years, effective February 11, 2002. This status distinguishes HearUSA from other hearing care providers and is widely used by our marketing efforts. If we are not able to maintain our accredited status, we will not be able to distinguish HearUSA on this basis and our revenues may suffer. Also, there is no assurance that JCAHO accreditation will extend to Helix centers or the network business.

***We are exposed to potential product and professional liability that could adversely affect us if a successful claim is made in excess of insurance policy limits.***

In the ordinary course of its business, HearUSA may be subject to product and professional liability claims alleging that products sold or services provided by the company failed or had adverse effects. We maintain liability insurance at a level which we believe to be adequate. A successful claim in excess of the policy limits of the liability insurance could materially adversely affect our business. As the distributor of products manufactured by others, we believe we would properly have recourse against the manufacturer in the event of a product liability claim. There can be no assurance, however, that recourse against a manufacturer by

HearUSA would be successful, or that any manufacturer will maintain adequate insurance or otherwise be able to pay such liability.

**Risks Relating to HearUSA Common Stock**

***The price of the common stock is volatile and could decline.***

The price of HearUSA common stock could fluctuate significantly, and you may be unable to sell your shares at a profit. There are significant price and volume fluctuations in the market generally that may be unrelated to our operating performance, but which nonetheless may adversely affect the market price for HearUSA common stock. The price of our common stock could change suddenly due to factors such as:

the amount of our cash resources and ability to obtain additional funding;

economic conditions in markets we are targeting;

fluctuations in operating results;

changes in government regulation of the healthcare industry;

failure to meet estimates or expectations of the market; and

rate of acceptance of hearing aid products in the geographic markets we are targeting.

Any of these conditions may cause the price of HearUSA common stock to fall, which may reduce business and financing opportunities available to us and reduce your ability to sell your shares at a profit, or at all.

***HearUSA might fail to maintain a listing for its common stock on the American Stock Exchange, making it more difficult for stockholders to dispose of or to obtain accurate quotations as to the value of their HearUSA stock.***

HearUSA common stock is presently listed on the American Stock Exchange. The American Stock Exchange will consider delisting a company's securities if, among other things,

the company fails to maintain stockholder's equity of at least \$2,000,000 if the company has sustained losses from continuing operations or net losses in two of its three most recent fiscal years;

the company fails to maintain stockholder's equity of \$4,000,000 if the company has sustained losses from continuing operations or net losses in three of its four most recent fiscal years; or

the company has sustained losses from continuing operations or net losses in its five most recent fiscal years.

HearUSA may not be able to maintain its listing on the American Stock Exchange, and there may be no public market for the HearUSA common stock. In the event the HearUSA common stock were delisted from the American Stock Exchange, trading, if any, in the common stock would be conducted in the over-the-counter market. As a result, you would likely find it more difficult to dispose of, or to obtain accurate quotations as to the market value of, your HearUSA common stock.

HearUSA has had sustained net losses in its five most recent fiscal years. On April 30, 2001, we were advised by the American Stock Exchange that it would review our progress toward eliminating losses, including our then-pending merger with Helix and our relationship with Siemens.

***If penny stock regulations apply to HearUSA common stock, you may not be able to sell or dispose of your shares.***

If HearUSA common stock were delisted from the American Stock Exchange, the penny stock regulations of the Securities and Exchange Commission might apply to transactions in the common stock. A penny stock generally includes any over-the-counter equity security that has a market price of less than \$5.00 per share. The Commission regulations require the delivery, prior to any transaction in a penny stock, of



a disclosure schedule prescribed by the Commission relating to the penny stock. A broker-dealer effecting transactions in penny stocks must make disclosures, including disclosure of commissions, and provide monthly statements to the customer with information on the limited market in penny stocks. These requirements may discourage broker-dealers from effecting transactions in penny stocks. If the penny stock regulations were to become applicable to transactions in shares of HearUSA common stock, they could adversely affect your ability to sell or otherwise dispose of your shares.

***Conversion of outstanding of HearUSA convertible subordinated notes and convertible preferred stock, and exercise of outstanding HearUSA options and warrants, could cause substantial dilution.***

As of May 31, 2004, outstanding convertible subordinated notes, convertible preferred stock, warrants and options of HearUSA included:

\$7.5 million in convertible subordinated notes, convertible into approximately 4,285,715 shares of common stock, assuming any interest is paid in cash (all of which notes are subject to contractual restrictions preventing their conversion prior to December 2005);

4,563 shares of 1998-E Series Convertible Preferred Stock, for which 4,000,000 shares of common stock have been reserved for issuance (all of which are subject to contractual restrictions preventing their conversion prior to November 2005, subject to certain exceptions);

Warrants to purchase approximately 5,209,893 shares of common stock (of which 3,609,893 are subject to contractual restrictions preventing their exercise prior to July, October or December 2005); and

Options to purchase approximately 3,451,458 shares of common stock.

Approximately 9,495,608 of the shares described above are covered by the registration statement of which this prospectus forms a part. To the extent outstanding subordinated notes or shares of preferred stock are converted, options or warrants are exercised or additional shares of capital stock are issued, stockholders receiving HearUSA common stock will incur additional dilution.

***Future sales of shares may depress the price of HearUSA common stock.***

If substantial stockholders sell shares of HearUSA common stock into the public market, or investors become concerned that substantial sales might occur, the market price of HearUSA common stock could decrease. Such a decrease could make it difficult for HearUSA to raise capital by selling stock or to pay for acquisitions using stock. There are 9,711,308 shares of HearUSA common stock covered by the registration statement of which this prospectus forms a part. In addition, HearUSA employees hold a significant number of options to purchase shares, many of which are presently exercisable. Employees may exercise their options and sell shares soon after such options become exercisable, particularly if they need to raise funds to pay for the exercise of such options or to satisfy tax liabilities that they may incur in connection with exercising their options.

***Because of the HearUSA rights agreement and the related rights plan for the exchangeable shares, a third party may be discouraged from making a takeover offer which could be beneficial to HearUSA and its stockholders.***

HearUSA has entered into a rights agreement with The Bank of New York, as rights agent. HEARx Canada Inc. has adopted a similar rights plan relating to the exchangeable shares of HEARx Canada Inc. issued in connection with the acquisition of Helix. The rights agreements contain provisions that could delay or prevent a third party from acquiring HearUSA or replacing members of the HearUSA board of directors, even if the acquisition or the replacements would be beneficial to HearUSA stockholders. The rights agreements could also result in reducing the price that certain investors might be willing to pay for shares of the common stock of HearUSA and making the market price lower than it would be without the rights agreement.

***Because HearUSA stockholders do not receive dividends, stockholders must rely on stock appreciation for any return on their investment in HearUSA.***

We have never declared or paid cash dividends on any of our capital stock. We currently intend to retain our earnings for future growth and, therefore, do not anticipate paying cash dividends in the future. As a result, only appreciation of the price of HearUSA common stock will provide a return to investors who purchase or acquire common stock pursuant to this prospectus.

#### **Other Risks Relating to the Business of HearUSA**

***We may not be able to access funds under our credit facility with Siemens if we cannot maintain compliance with the restrictive covenants contained therein, and we may incur a substantial penalty upon a change of control.***

On December 7, 2001, HearUSA and Siemens Hearing Instruments Inc. entered into a credit agreement pursuant to which HearUSA obtained a \$51,875,000 secured credit facility from Siemens, which was amended in March 2003 to add a \$3,500,000 secured loan facility. As of March 27, 2004, an aggregate of \$23,347,577 in loans was outstanding under the credit facility. To continue to access the credit facility, we are required to comply with the terms of the credit facility, including compliance with restrictive covenants. There can be no assurance that we will be able to comply with these restrictive covenants in the future and, accordingly, may be unable to access the funds provided under the credit facility. In addition, if we are unable to comply with these restrictive covenants, we may be found in default by Siemens and face other penalties under the credit agreement. As part of our agreement with Siemens, if we undergo a change of control resulting from the sale of HearUSA to another manufacturer of hearing aids or related products and terminate our agreements with Siemens, we must pay \$50 million to Siemens. HearUSA and Siemens have agreed that the Helix acquisition did not constitute a change of control for this purpose.

***We may not be able to obtain additional capital on reasonable terms, or at all, to fund our operations.***

If capital requirements vary from those currently planned or losses are greater than expected, HearUSA may require additional financing. If additional funds are raised through the issuance of convertible debt or equity securities, the percentage ownership of existing stockholders may be diluted, the securities issued may have rights and preferences senior to those of stockholders, and the terms of the securities may impose restrictions on operations. If adequate funds are not available on reasonable terms, or at all, we will be unable to take advantage of future opportunities to develop or enhance our business or respond to competitive pressures and possibly even to remain in business.

***Future acquisitions or investments could negatively affect our operations and financial results or dilute the ownership percentage of our stockholders.***

We expect to review acquisition and investment prospects that would complement or expand our current services or otherwise offer growth opportunities. We may have to devote substantial time and resources in order to complete potential acquisitions. We may not identify or complete acquisitions in a timely manner, on a cost-effective basis, or at all.

In the event of any future acquisitions, HearUSA could:

issue additional stock that would further dilute our current stockholders' percentage ownership;

incur debt;

assume unknown or contingent liabilities; or

experience negative effects on reported operating results from acquisition-related charges and amortization of acquired technology, goodwill and other intangibles.





## Edgar Filing: HEARUSA INC - Form 424B3

after December 2005 until December 2008. The warrants have an exercise price of \$1.75 per share and contain cashless exercise provisions. 500,000 warrants were issued to a consultant in connection with this private placement. These warrants also have an exercise price of \$1.75 per share and contain cashless exercise provisions. They may be exercised at any time after July 2005.

800,000 shares of the common stock offered by this prospectus are issuable pursuant to warrants that were issued to investors in our \$2 million private placement of unsecured notes in October 2003. The notes have been repaid and are no longer outstanding. These warrants may be exercised at any time from and after October 2005 through October 2010 at an exercise price of \$1.25 per share (for 240,000 of these warrants) and \$1.31 per share (for 560,000 of these warrants).

Of the shares of common stock offered by this prospectus, 100,000 shares are issuable upon the exercise of warrants issued in November 2002 to Adelpia Holdings, LLC and Barry A. Bloomfield in exchange for consulting services. The warrants may be exercised at any time until November 25, 2005 at an exercise price of \$1.00 per share. In addition, 50,000 shares of the common stock offered by this prospectus are issuable upon the exercise of a warrant issued in April 2004 to Barry A. Bloomfield in exchange for consulting services. The warrant may be exercised at any time from October 1, 2005 to April 16, 2007 at an exercise price of \$3.00 per share.

200,000 shares of the common stock offered by this prospectus were issued to The Kriegsman Group in connection with consulting services extended to the company.

An additional 1,500,000 shares offered by this prospectus are issuable upon the exercise of warrants issued to investors in a private placement that closed in March 2002. The warrants may be exercised at any time until March 29, 2005 at an exercise price of \$1.15 per share.

The remaining 15,700 shares of common stock offered by this prospectus were issued in December 2001 and July 2002 to Kennebec Resources, Inc. in exchange for financial services rendered to HearUSA.

The following table sets forth the names of the selling shareholders, the number of shares of common stock beneficially owned by each selling shareholder, the number of shares that may be offered for resale under this prospectus, the number of shares and percentage (if greater than one percent) of common stock that will be beneficially owned by the selling shareholders after this offering is completed. The number of shares in the column *Shares Being Offered* represents all of the shares that the selling shareholders may offer under this prospectus. We do not know how long the selling shareholders will hold the shares before selling them. The selling shareholders are not required to sell all or any shares offered by this prospectus. The table assumes that all shares being offered in this offering are sold to non-affiliates of the selling shareholders.

Edgar Filing: HEARUSA INC - Form 424B3

As shown in the following table, certain of the selling shareholders are, or are affiliates of, directors and/or officers of HearUSA. None of the other selling shareholders have had any position, office or other material relationship with HearUSA within the past three years except as a result of the ownership of the shares offered by this prospectus.

Name of Selling Shareholder	Shares Beneficially Owned Prior to Offering	Shares Being Offered	Shares Beneficially Owned After Offering	% of Common Stock Beneficially Owned After Offering (if greater than 1%)
Adelphia Holdings, LLC	50,000	50,000	0	
Alexandra Global Master Fund	857,129(1)	857,129(1)	0	
Thomas W. Archibald(2)	240,100	50,000	190,100	
Atlas Capital Master Fund, L.P.	1,285,693(1)	1,285,693(1)	0	
Atlas Capital (Q.P.) L.P.	428,564(1)	428,564(1)	0	
Barry A. Bloomfield	100,000(4)	100,000(4)	0	
Paul A. Brown, M.D.(3)	2,625,000(4)	695,000(4)	1,930,000	6.34%
Flyline Holdings, Ltd.	428,564(1)	428,564(1)	0	
Gestion Fremican Inc.(5)	893,928(4)	160,000(4)	733,928	2.41%
Stephen J. Hansbrough(6)	746,750	100,000	646,750	2.13%
Jesup & Lamont Securities Corporation	40,000(7)	40,000(7)	0	
Joseph L. Gitterman III(2)	334,764	150,000	184,764	
J.P. Carey Securities, Inc.	57,143(7)	57,143(7)	0	
Kennebec Resources, Inc.	444,264(8)	444,264(8)	0	
The Kriegsman Group	200,000	200,000	0	
David J. McLachlan(2)	179,295	50,000	129,295	
Micro Capital Fund Ltd.	128,569(1)	128,569(1)	0	
Micro Capital Fund LP	299,995(1)	299,995(1)	0	
Millicom 2000 Grat	857,129(1)	857,129(1)	0	
175778 Canada, Inc.(9)	236,046(4)	160,000(4)	76,046	
Richard Press	500,000(4)	140,000(4)	360,000	1.18%
Brandon Ross	16,000(7)	16,000(7)	0	
Louis Schwartz	25,400	10,000	15,400	
Chris Sebastian	15,000	10,000	5,000	
Andrew Siegel	150,000	75,000	75,000	
Jack Silver	1,000,000(10)	1,000,000(10)	0	
Paul Silverstein, M.D.	200,000	100,000	100,000	
Sherleigh Associates Inc. Profit Sharing Plan	1,714,258(1)	1,714,258(1)	0	
George Tabuas	4,000(7)	4,000(7)	0	
Herbert Weiss	23,000	15,000	8,000	
Robert Willis, M.D.	515,000(11)	85,000(11)	430,000	1.41%
<b>Total</b>	<b>14,595,591</b>	<b>9,711,308</b>	<b>4,884,283</b>	

- (1) Assumes conversion of HearUSA 2003 convertible subordinated notes due November 30, 2008 (the "Notes") at a conversion price of \$1.75, with all accrued interest paid in cash, and exercise of warrants issued in connection therewith (the "Notes Warrants"). Includes shares underlying Notes and Notes Warrants exercisable only after December 2005. Includes shares underlying Notes Warrants to purchase a number of shares of common stock that, when taken together with the number of shares of common stock issuable upon conversion of the Notes currently outstanding and exercise of the other Notes Warrants currently outstanding, could exceed the number of shares of common stock that may be issued without shareholder approval under the rules and regulations of the American Stock Exchange.

## Edgar Filing: HEARUSA INC - Form 424B3

- (2) Director of HearUSA.
- (3) Chairman of the Board of HearUSA.
- (4) Includes shares underlying warrants exercisable only after October 2005.
- (5) Michel Labadie, a director of HearUSA, is a director and shareholder of this company. The shares reflected in the table as beneficially owned by Mr. Labadie's company excludes 42,685 shares subject to options owned by Mr. Labadie in his individual capacity, and 1,485,540 shares and 106,110 shares subject to options which are owned by Les Partenaire de Montréal, s.e.c. ( Montreal Partners ). Mr. Labadie is a director of Les Partenaires de Montréal Inc., the general partner of Montreal Partners.
- (6) Chief Executive Officer and director of HearUSA.
- (7) Includes shares underlying warrants exercisable only after December 2005.
- (8) Includes 428,564 shares underlying the Notes and Notes Warrants (see footnote 1).
- (9) Pierre Bourgie, a director of HearUSA, is a director and shareholder of this company. The shares reflected in the table as beneficially owned by Mr. Bourgie's company excludes 25,000 shares subject to options owned by Mr. Bourgie in his individual capacity, and 1,485,540 shares and 106,110 shares subject to options which are owned by Montreal Partners. Mr. Bourgie is a director of Les Partenaires de Montréal Inc., the general partner of Montreal Partners.
- (10) Includes 300,000 shares underlying warrants currently exercisable, 200,000 shares underlying warrants exercisable only after October 2005 and 500,000 shares underlying warrants exercisable only after July 2005.
- (11) Includes shares held by trusts of which Mr. Willis serves as trustee.

### PLAN OF DISTRIBUTION

The selling shareholders and any of their pledgees, assignees and successors in interest may, from time to time, sell any or all of their shares of common stock on any stock exchange, market or trading facility on which the shares are traded or in private transactions. These sales may be at fixed or negotiated prices. The selling shareholders may use any one or more of the following methods when selling shares:

ordinary brokerage transactions and transactions in which the broker dealer solicits purchasers;

block trades in which the broker dealer will attempt to sell the shares as agent but may position and resell a portion of the block as principal to facilitate the transaction;

purchases by a broker dealer as principal and resale by the broker dealer for its account;

an exchange distribution in accordance with the rules of the applicable exchange;

privately negotiated transactions;

broker dealers may agree with the selling shareholder to sell a specified number of such shares at a stipulated price per share;

a combination of any such methods of sale; and

any other method permitted pursuant to applicable law.

The selling shareholders may also sell shares under Rule 144 under the Securities Act of 1933, if available, rather than under this prospectus.

## Edgar Filing: HEARUSA INC - Form 424B3

The selling shareholders may pledge their shares to their brokers under the margin provisions of customer agreements. If the selling shareholders default on a margin loan, the broker may, from time to time, offer and sell the pledged shares.

Broker dealers engaged by the selling shareholders may arrange for other brokers dealers to participate in sales. Broker dealers may receive commissions or discounts from the selling shareholders (or, if any broker dealer acts as agent for the purchaser of shares, from the purchaser) in amounts to be negotiated. The selling

shareholders do not expect these commissions and discounts to exceed what is customary in the types of transactions involved.

The selling shareholders and any broker dealers or agents that are involved in selling the shares may be deemed to be underwriters within the meaning of the Securities Act in connection with such sales. In such event, any commissions received by such persons and any profit on the resale of the shares purchased by them may be deemed to be underwriting commissions or discounts under the Securities Act.

HearUSA is required to pay all fees and expenses incident to the registration of the shares, but is not obligated and will not pay any commissions or discounts in connection with the sales to be made by the selling shareholders. HearUSA has agreed to indemnify certain of the selling shareholders and these selling shareholders have agreed to indemnify HearUSA against certain losses, claims, damages and liabilities, including liabilities under the Securities Act.

### COMMON STOCK

Each share of HearUSA common stock trades with and has attached to it a right to purchase shares of preferred stock. The terms of the rights are set forth in an amended and restated rights agreement dated as of July 11, 2002, between HearUSA and The Bank of New York, as rights agent. Each right entitles the holder to purchase from HearUSA one one-hundredth of a share of Series H Junior Participating Preferred Stock, par value \$1.00 per share, at a price of \$28.00, subject to adjustment. The rights will be evidenced by common stock certificates and are not exercisable until the earlier of:

the close of business on the tenth business day following the date of public announcement of or the date on which HearUSA first has notice or determines that a person or group of affiliated or associated persons has acquired, or has obtained the right to acquire, 15% or more of the outstanding shares of HearUSA voting stock without the prior express written consent of the Board of Directors, or

the close of business on the tenth business day following the commencement of a tender offer or exchange offer by a person, without the prior written consent of the Board of Directors, which offer, upon consummation would result in such person's control of 15% or more of HearUSA voting stock.

If not exercised by the holders or earlier redeemed or exchanged by HearUSA, the rights will expire on December 14, 2009. The purchase price payable, and the number of share of Series H preferred stock or other securities or property issuable, upon exercise of the rights are subject to adjustment from time to time to prevent dilution by action of the Board of Directors and in circumstances described in the Rights Agreement.

### AVAILABLE INFORMATION

We have filed with the Securities and Exchange Commission, Washington, DC 20549, a registration statement on Form S-3 under the Securities Act with respect to the shares of common stock offered by this prospectus. This prospectus does not contain all of the information set forth in the registration statement and the exhibits and schedules filed with the registration statement. Certain items are omitted in accordance with the rules and regulations of the Commission. For further information with respect to HearUSA and the common stock offered by this prospectus, reference is made to the registration statement and the exhibits and schedules filed with the registration statement. Statements contained in this prospectus as to the contents of any contract or any other document referred to are not necessarily complete, and in each instance, reference is made to the copy of such contract or other document filed as an exhibit to the registration statement, each such statement being qualified in all respects by such reference.

A copy of the registration statement, and the exhibits and schedules filed with it, may be inspected without charge at the public reference facilities maintained by the Commission in Room 1024, 450 Fifth Street, NW, Washington, DC 20549, and the Commission's regional office located at the Northwestern Atrium Center, 500 West Madison Street, Suite 1400, Chicago, Illinois 60661, and copies of all or any part of the registration statement may be obtained from such offices upon the payment of the fees prescribed by the Commission. The public may obtain information on the operation of the public reference room by calling the Commission at 1-800-SEC-0330. The Commission maintains a World Wide Web site that contains reports, proxy and information statements and other information regarding registrants that file electronically with the

## Edgar Filing: HEARUSA INC - Form 424B3

Commission, including HearUSA. The address of the site is <http://www.sec.gov>. The registration statement, including all its exhibits and amendments, has been filed electronically with the Commission.

### INFORMATION INCORPORATED BY REFERENCE

The Commission allows us to incorporate by reference the information we provide in documents filed with the Commission, which means that we can disclose important information by referring to those documents. The information incorporated by reference is an important part of this prospectus. Any statement contained in a document that is incorporated by reference in this prospectus is automatically updated and superseded if information contained in this prospectus, or information that we later file with the Commission, modifies and replaces this information. We incorporate by reference the following documents we have filed with the Commission:

- (a) Annual Report on Form 10-K, as amended on Form 10-K/A, for the fiscal year ended December 27, 2003 (File No. 001-11655);
- (b) Quarterly Report on Form 10-Q for the fiscal quarter ended March 27, 2004 (File No. 001-11655);
- (c) The consolidated financial statements of Helix Hearing Care of America Corp. as of November 30, 2001 and 2000 and for the years ended November 30, 2001, 2000 and 1999 and report thereon by Deloitte & Touche LLP, independent registered chartered accountants, dated February 15, 2002 (except for Note 18b which is dated May 3, 2002), included in the company's Form S-4 (Reg. No. 333-73022); and
- (d) The description of the common stock contained in the company's Registration Statement on Form 8-A, filed on March 4, 1996 (File No. 001-11655).

In addition, all documents filed by HearUSA with the Commission under Sections 13(a), 13(c), 14 or 15(d) of the Securities Exchange Act of 1934 (other than those deemed furnished on Form 8-K) after the date of this prospectus and prior to the filing of a post-effective amendment that indicates that all securities offered hereby have been sold or that deregisters all securities remaining unsold, will be considered to be incorporated by reference into this prospectus and to be a part of this prospectus from the dates of the filing of such documents.

You may get copies of any of the incorporated documents (excluding exhibits, unless the exhibits are specifically incorporated) at no charge to you by writing or calling Secretary, HearUSA, Inc., 1250 Northpoint Parkway, West Palm Beach, Florida 33407, telephone (561) 478-8770.

### LEGAL MATTERS

The legality of the shares of common stock offered by this prospectus has been passed upon for HearUSA by Bryan Cave LLP, Washington, D.C.

### EXPERTS

The consolidated financial statements and schedule of HearUSA, Inc. incorporated by reference in this prospectus, have been audited by BDO Seidman, LLP, independent certified public accountants, to the extent and for the periods set forth in their report incorporated herein by reference, and are incorporated herein in reliance upon such report given upon the authority of said firm as experts in auditing and accounting.

The consolidated financial statements of Helix Hearing Care of America Corp. as of November 30, 2001 and 2000 and for the years ended November 30, 2001, 2000 and 1999 incorporated in this prospectus by reference to the company's Joint Proxy Statement/ Prospectus on Form S-4 (Reg. No. 333-73022) have been audited by Deloitte & Touche LLP, independent registered chartered accountants, as stated in their report, which is incorporated herein by reference, and has been so incorporated in reliance upon the report of such firm given their authority as experts in accounting and auditing.